COVID-19 in patients with rheumatological diseases in the Eastern Province of Saudi Arabia.

The severity of the 2019 coronavirus disease (COVID-19) and its effects remain unpredictable. Certain factors, such as obesity, hypertension, and type 2 diabetes mellitus, may increase the severity of the disease. Rheumatology experts suggest that patients with active autoimmune conditions and controlled autoimmune diseases on immunosuppressive therapy may be at higher risk of developing severe COVID-19.

Bacteremia in a Patient with Human Immunodeficiency Virus Infection: A Case Report and Literature Review.

() is clinically important due to its association with underlying medical conditions. Infection with may worsen HIV prognosis, leading to acquired immunodeficiency syndrome. However, it is not frequently isolated and its susceptibility to antibiotics has not been well studied.

The Impact of Diabetes Mellitus and Hyperglycemia on the Severity and Outcome of Patients with COVID-19 Disease: A Single-Center Experience.

Purpose: Diabetes mellitus (DM) has been reported to be associated with a  worse outcome of COVID-19 infection. The evidence is scarce in the Middle East and Saudi Arabia. We aimed to evaluate the impact of diabetes mellitus and hyperglycemia in non-diabetic individuals on the severity and outcome of COVID-19 infection.

Co-existence of BKV nephropathy and disseminated tuberculosis in transplant recipient.

Tuberculosis (TB) in renal transplant recipients presents important diagnostic difficulties because of the greater incidence of extra-pulmonary involvement, negative sputum smear results despite active disease and its atypical presentation, specifically reactivation of the latent form. BKV nephropathy was first reported in 1995, coinciding with the widespread use of immunosuppressive drugs, which can complicate the cores of 1-10% of renal transplant recipients. It is also not uncommon to find the existence of bacterial or fungal infections in the presence of an immuno-modulating virus like cytomegalovirus infection.

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.

In a phase I/II trial assessing the toxicity, pharmacokinetics, and activity of the (-)enantiomer of 2'-deoxy-3'-thiacytidine (3TC, lamivudine), 97 patients with AIDS or advanced human immunodeficiency virus (HIV) disease were administered 3TC at 0.5-20.0 mg/kg/day.